GSK Competitive Strategy & Market Position
GSK's advantages are scale in vaccine manufacturing, a long-acting HIV portfolio through ViiV Healthcare, and the AS01 adjuvant system used in Shingrix and Arexvy. Vaccines are hard to copy because they depend on biological manufacturing, cold-chain distribution and long-term government contracts. ViiV's long-acting injectables, Cabenuva for treatment and Apretude for prevention, aim to move patients onto newer regimens ahead of the dolutegravir patent expiry.
- Who are GSK's competitors?
- GSK's main competitors covered here are Pfizer, Abbvie and Johnson And Johnson.
- What is GSK's market share?
- GSK plc is one of the premier market leaders in Pharmaceuticals & Biotechnology, commanding substantial market share and strong brand equity across its core geographic operating regions.
Core Strength
Vaccines generated ~$12.1 billion (£9.2 billion) in 2025, led by Shingrix (~$4.75 billion (£3.6 billion)) and meningitis vaccines (~$2.11 billion (£1.6 billion)), backed by large biological manufacturing capacity and the AS01 adjuvant system.
Key Weakness
HIV sales of ~$10.2 billion (£7.7 billion) rely heavily on dolutegravir-based regimens, which lose exclusivity between 2028 and 2030.
Market Position & Competitive Landscape
GSK competes with Pfizer, Merck & Co., Sanofi and Moderna in vaccines; with Gilead Sciences in HIV, where Gilead's Biktarvy and the twice-yearly lenacapavir (Yeztugo) for prevention challenge ViiV; with AstraZeneca and Sanofi/Regeneron (Dupixent) in respiratory and immunology; and with AstraZeneca, Merck and Roche in oncology. GSK is smaller than AstraZeneca, the UK's largest drugmaker, and in mid-2026 its market value of roughly $99 billion (£75 billion) was well below its main US peers. Its response has been to buy late-stage oncology and specialty assets (IDRx, efimosfermin, Nuvalent) and accelerate its own pipeline, targeting more than 20 phase III trial starts in 2026.
Key Competitors
| Competitor | Profile |
|---|---|
| Pfizer | View Profile → |
| Abbvie | View Profile → |
| Johnson And Johnson | View Profile → |
GSK Competitors, SWOT and Strategy FAQ
How does GSK compete against Gilead Sciences in the global HIV market?
GSK's ViiV Healthcare competes by pioneering two-drug regimens (Dovato) that reduce drug burden compared to Gilead's three-drug Biktarvy, while establishing commercial dominance in long-acting injectable treatment (Cabenuva) and long-acting prevention (Apretude) to counter daily oral pills.
How does GSK maintain commercial leadership in adult RSV immunization with Arexvy?
GSK won first-to-market advantage with Arexvy, demonstrating over 82% overall efficacy and 94% efficacy against severe RSV in older adults with comorbidities. GSK secured dominant pharmacy retail distribution partnerships in the US, capturing majority market share over Pfizer's Abrysvo.
What is GSK's competitive strategy in oncology centered around Jemperli (dostarlimab)?
Jemperli is GSK's anti-PD-1 checkpoint inhibitor. GSK established Jemperli as the first-line standard of care for dMMR/MSI-H advanced endometrial cancer, and generated historic 100% complete clinical remission rates in landmark rectal cancer clinical trials, expanding into broad solid tumor combinations.
How does GSK utilize functional genomics and artificial intelligence in drug discovery?
GSK partners with 23andMe and the UK Biobank, leveraging vast human genetic databases and AI machine learning algorithms to identify disease targets with genetic validation, doubling the probability of clinical trial success compared to traditional drug discovery.
What is GSK's competitive approach to respiratory medicine against AstraZeneca and Sanofi?
GSK leads the inhaled maintenance market with Trelegy Ellipta (combining ICS/LABA/LAMA in a single once-daily dry powder inhaler) while commercializing Nucala (anti-IL-5 monoclonal antibody) for severe eosinophilic asthma, COPD, and rare eosinophilic diseases.
How does GSK expand vaccine access across low- and middle-income nations?
GSK supplies millions of affordable pediatric and maternal vaccines to UNICEF and Gavi, developed the world's first malaria vaccine (Mosquirix), and established tiered pricing frameworks that enable developing nations to protect vulnerable populations.
What is GSK's strategy regarding mRNA vaccine technology and manufacturing?
GSK acquired CureVac's mRNA vaccine assets, securing full intellectual property ownership of proprietary second-generation multivalent mRNA vaccine candidates for seasonal influenza, COVID-19 combination shots, and avian flu pandemic preparedness.
How does GSK defend its core intellectual property against generic challenges?
GSK protects its innovations through extensive global patent portfolios covering novel crystalline chemical forms, combination drug formulations, dry powder inhalation delivery devices (Ellipta), and complex biologics manufacturing trade secrets.
What is GSK's competitive advantage?
Their absolute moat is vaccine manufacturing. Building a facility to safely mass-produce billions of vaccines is incredibly expensive and highly regulated. GSK's Shingrix vaccine (for shingles) is considered a massive scientific triumph, boasting a 90%+ efficacy rate and generating billions in near-monopoly revenue.